HanAll Biopharma Ranks Among Top 100 KOSPI Stocks by Share Price Gain in First Half

[NEWSMP] Pharmaceutical stocks struggled throughout the first half of the year.

Among the 49 constituents of the KOSPI Pharmaceutical Index (excluding preferred shares), only four posted gains during the first half of the year, while 44 recorded declines (based on adjusted share prices).

According to the Korea Exchange, while the KOSPI Index surged more than 100% during the first half of the year, the KOSPI Pharmaceutical Index underperformed, falling 14.15% over the same period.

Among the 944 KOSPI-listed companies whose share prices were comparable between the beginning of the year and the end of June, HanAll Biopharma was the only constituent of the KOSPI Pharmaceutical Index to rank among the top 100 gainers.

In contrast, 10 of the 49 Pharmaceutical Index constituents ranked among the 100 biggest decliners on the KOSPI.

By company, HanAll Biopharma's share price climbed 42.6% during the period, ranking 81st among the 944 KOSPI-listed companies and making it the only Pharmaceutical Index constituent to rank among the top 100 gainers.

Bukwang Pharmaceutical also posted a double-digit gain of 13.1%, ranking 180th and securing a place among the top 200.

In addition, JW Pharmaceutical and Celltrion recorded marginal gains of 0.8% and 0.5%, respectively. Although neither gained more than 1%, they ranked 279th and 284th, placing them within the top 300. Dongsung Bio Pharm, whose shares were suspended from trading, also ranked within the top 300, coming in at 294th.

Conversely, the remaining 44 constituents all posted declines, placing them outside the top 300 in terms of share price performance. Of these, 38 stocks recorded double-digit losses, while five declined by more than 50%.

Notably, Aprogen posted the largest share price decline among the 944 KOSPI-listed companies, with its stock plunging 79.3% during the period. Aprogen Biologics followed with a 75.0% decline.

GeneOne Life Science also fell 72.7%, marking the fourth-largest share price decline among KOSPI-listed companies. As a result, pharmaceutical stocks accounted for more than half of the five biggest decliners on the KOSPI during the first half of the year.

Ildong Pharmaceutical and Ildong Holdings also fell 56.1% and 53.7%, respectively, both declining by more than 50% and ranking 35th and 52nd among decliners.

IL-Yang Pharm, Yungjin Pharm, and Shin Poong Pharm each fell by more than 40%. Together with Myung In Pharm, which declined 39.7%, and Yuhan Corporation, which fell 37.5%, these five companies ranked among the 100 biggest decliners.

In addition, Handok, CKD Bio, Daewoong Pharmaceutical, Daewon Pharmaceutical, Hyundai Pharm, Jeil Pharmaceutical, Dong-A ST, Samil Pharmaceutical, and Myungmoon Pharm all recorded declines of more than 30%. PharmGen Science also fell 29.7%, bringing the total to 20 Pharmaceutical Index constituents among the 200 biggest decliners.

Other Pharmaceutical Index constituents—including Orient Bio, SK Bioscience, GC Biopharma, Daewoong, Kukje Pharma, Hana Pharm, and Chong Kun Dang Pharmaceutical—also posted declines of more than 20%. In total, 27 of the 49 Pharmaceutical Index constituents ranked among the 300 biggest decliners on the KOSPI.